{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:08:27Z","timestamp":1789549707074,"version":"build-2803163510"},"reference-count":0,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Background and aim: Clinical trials have demonstrated the efficacy of fixed-dose combination calcipotriol\/betamethasone (Cal\/BD) aerosol foam for the treatment of patients with scalp psoriasis. However, data on the real-world effectiveness of Cal\/BD aerosol foam in this subgroup of patients are lacking. Therefore, this study investigated the effectiveness and tolerability of 4 weeks\u2019 treatment with Cal\/BD aerosol foam in patients with scalp psoriasis in everyday clinical practice. Methods: This prospective, non-interventional multicenter study involved 217 adults with scalp psoriasis who were treated with Cal\/BD aerosol foam for 4 weeks. Primary endpoints included the proportion of patients with &lt;10% of the scalp area affected (Scalp-BSA) plus a Scalp-PGA of \u201cmild\u201d after 4 weeks, as well as the proportion of patients with an absolute PSSI \u22642 points after 4 weeks. Secondary endpoints included patient reported changes in erythema, itching, flaking, and thickness at baseline, 3 days, 1 week, 2 weeks, and 4 weeks. Results: After 4 weeks, 53.4% of patients treated with Cal\/BD aerosol foam had achieved a Scalp-BSA of &lt;10% and a mild Scalp-PGA. Furthermore, 47.6% of patients achieved a PSSI \u22642. Improvements in pruritus and other symptoms (induration, erythema, and scaling) were seen already within 3 days. The proportion of patients who reported that scalp psoriasis had no influence on their quality of life (Dermatology Quality of Life Index 0\/1 points) increased from 3.2% at baseline to 47.9% at study end. Patient satisfaction with treatment was high (Treatment Satisfaction Questionnaire-9 scores of 74.5 \u00b1 27.1 for effectiveness, 72.0 \u00b1 25.2 for ease of use, and 77.8 \u00b1 24.2 for general satisfaction). Overall, 97.4% of HCPs assessed the tolerability of Cal\/BD aerosol foam as good\/very good with no new safety concerns. Conclusion: This study demonstrated the effectiveness, rapid onset of action, good tolerability, and good safety profile of the Cal\/BD aerosol foam in patients with scalp psoriasis treated in a real-world setting. <\/jats:p>","DOI":"10.1159\/000527496","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T22:00:26Z","timestamp":1675116026000},"page":"206-216","source":"Crossref","is-referenced-by-count":2,"title":["Prospective Observational Evaluation of Fixed Combination Calcipotriol\/Betamethasone Aerosol Foam (Enstilar\u00ae) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study)"],"prefix":"10.1159","volume":"239","author":[{"given":"Petra","family":"Staubach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wurzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4415","authenticated-orcid":false,"given":"Hans Joachim","family":"Hutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"von Kiedrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2023,1,30]]},"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/drm\/article-pdf\/239\/2\/206\/3951149\/000527496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/drm\/article-pdf\/239\/2\/206\/3951149\/000527496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:27:48Z","timestamp":1745422068000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000527496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,2]]},"published-print":{"date-parts":[[2023,3,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000527496","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}